{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:57Z","timestamp":1791232497475,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Thrombosis is a major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN), while bleeding is also common. Current thrombosis and bleeding risk stratification strategies are limited, creating a need for identification of novel risk factors to better predict these complications.\u00a0We performed laboratory coagulation testing and driver mutation profiling from peripheral blood of patients with MPN. Patients\u2019 history of comorbidities, hematological variables and thrombosis and\/or bleeding events were collected retrospectively at the time of testing. Patients were then followed for a median of 3.3 years for incident events.\u00a0198 patients were included in the study. Thrombotic events occurred in 41% of the patients. Age, cardiovascular comorbidities and constitutional symptoms were significantly associated with thrombosis, as well as elevated von Willebrand Factor (vWF): Antigen, vWF: Activity and factor VIII levels. Elevated vWF: Antigen levels remained independent in multivariate analysis and were predictive of incident thrombosis. Bleeding events occurred in 26% of the patients. vWF: Activity\u2009\u2264\u200930%, vWF: Activity-to-antigen ratio of \u2264\u20090.7, a platelet count of \u2265\u2009500*10\n                    <jats:sup>9<\/jats:sup>\n                    \/L and\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F variant allele frequency (VAF) of \u2265\u200950% were predictive of total (including minor) bleeding events. However, only\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F VAF of \u2265\u200950% was predictive of major and clinically relevant non-major bleeding. Extreme thrombocytosis defined by a platelet count of \u2265\u20091000*10\n                    <jats:sup>9<\/jats:sup>\n                    \/L was not associated with bleeding or acquired vWF syndrome.\u00a0vWF profiling and\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F VAF contribute to thrombosis and bleeding risk assessment in patients with MPNs and should be incorporated routinely at diagnosis and during follow-up.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06648-9","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:42:49Z","timestamp":1760416969000},"page":"5085-5094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms"],"prefix":"10.1007","volume":"104","author":[{"given":"Ayala","family":"Gat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romi","family":"Kazoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ela","family":"Shai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Roth Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Buchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Kalish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"16","key":"6648_CR1","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1182\/blood.2020008109","volume":"137","author":"HC Hasselbalch","year":"2021","unstructured":"Hasselbalch HC, Elvers M, Schafer AI (2021) The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood 137(16):2152\u20132160. https:\/\/doi.org\/10.1182\/blood.2020008109","journal-title":"Blood"},{"issue":"5","key":"6648_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW et al (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168(5):317\u2013325. https:\/\/doi.org\/10.7326\/M17-0028","journal-title":"Ann Intern Med"},{"issue":"1","key":"6648_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5387-9","volume":"19","author":"T Rungjirajittranon","year":"2019","unstructured":"Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T (2019) A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer 19(1):184. https:\/\/doi.org\/10.1186\/s12885-019-5387-9","journal-title":"BMC Cancer"},{"issue":"4","key":"6648_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M et al (2019) 3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 94(4):599\u2013610. https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.022","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"6648_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/14737140.2018.1457441","volume":"18","author":"E Zimran","year":"2018","unstructured":"Zimran E, Hoffman R, Kremyanskaya M (2018) Current approaches to challenging scenarios in myeloproliferative neoplasms. Expert Rev Anticancer Ther 18(6):567\u2013578. https:\/\/doi.org\/10.1080\/14737140.2018.1457441","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"6648_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","volume":"12","author":"K Martin","year":"2017","unstructured":"Martin K (2017) Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep 12(5):389\u2013396. https:\/\/doi.org\/10.1007\/s11899-017-0400-3","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"6648_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11239-019-02029-y","volume":"49","author":"FS Seguro","year":"2020","unstructured":"Seguro FS, Teixeira LLC, da Rosa LI et al (2020) Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. J Thromb Thrombolysis 49(4):667\u2013672. https:\/\/doi.org\/10.1007\/s11239-019-02029-y","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"6648_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/ajh.24269","volume":"91","author":"A Andriani","year":"2016","unstructured":"Andriani A, Latagliata R, Anaclerico B et al (2016) Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients. Am J Hematol 91(3):318\u2013321. https:\/\/doi.org\/10.1002\/ajh.24269","journal-title":"Am J Hematol"},{"issue":"1","key":"6648_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3324\/haematol.2016.152769","volume":"102","author":"A Alvarez-Larr\u00e1n","year":"2017","unstructured":"Alvarez-Larr\u00e1n A, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F et al (2017) Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica 102(1):103\u2013109. https:\/\/doi.org\/10.3324\/haematol.2016.152769","journal-title":"Haematologica"},{"issue":"6","key":"6648_CR10","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","volume":"109","author":"A Carobbio","year":"2007","unstructured":"Carobbio A, Finazzi G, Guerini V et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109(6):2310\u20132313. https:\/\/doi.org\/10.1182\/blood-2006-09-046342","journal-title":"Blood"},{"issue":"16","key":"6648_CR11","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood.2023020232","volume":"143","author":"AT Gerds","year":"2024","unstructured":"Gerds AT, Mesa R, Burke JM et al (2024) Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood 143(16):1646\u20131655. https:\/\/doi.org\/10.1182\/blood.2023020232","journal-title":"Blood"},{"issue":"2","key":"6648_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00625-5","volume":"12","author":"A Carobbio","year":"2022","unstructured":"Carobbio A, Vannucchi AM, De Stefano V et al (2022) Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J 12(2):28. https:\/\/doi.org\/10.1038\/s41408-022-00625-5","journal-title":"Blood Cancer J"},{"issue":"16","key":"6648_CR13","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN (2023) JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood 141(16):1934\u20131942. https:\/\/doi.org\/10.1182\/blood.2022017697","journal-title":"Blood"},{"issue":"2","key":"6648_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","volume":"38","author":"H Pasquer","year":"2024","unstructured":"Pasquer H, Daltro de Oliveira R, Vasseur L et al (2024) Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia 38(2):326\u2013339. https:\/\/doi.org\/10.1038\/s41375-023-02114-5","journal-title":"Leukemia"},{"issue":"Supp. 1","key":"6648_CR15","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2024-209783","volume":"144","author":"A Haran","year":"2024","unstructured":"Haran A, Wasserstrom A, Aumann S (2024) DNMT3A, TET2, and ASXL1 (DTA) mutations are associated with thrombosis and bleeding in patients with myeloproliferative neoplasms. Blood 144(Supp. 1):3189","journal-title":"Blood"},{"issue":"9","key":"6648_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood.2020008043","volume":"137","author":"AR Moliterno","year":"2021","unstructured":"Moliterno AR, Ginzburg YZ, Hoffman R (2021) Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood 137(9):1145\u20131153. https:\/\/doi.org\/10.1182\/blood.2020008043","journal-title":"Blood"},{"issue":"6","key":"6648_CR17","volume":"88","author":"AB Federici","year":"2003","unstructured":"Federici AB (2003) The factor VIII\/von willebrand factor complex: basic and clinical issues. Haematologica 88(6):EREP02","journal-title":"Haematologica"},{"issue":"22","key":"6648_CR18","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood.2021011494","volume":"138","author":"MS Edvardsen","year":"2021","unstructured":"Edvardsen MS, Hansen ES, Hindberg K et al (2021) Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. Blood 138(22):2269\u20132277. https:\/\/doi.org\/10.1182\/blood.2021011494","journal-title":"Blood"},{"issue":"11","key":"6648_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","volume":"117","author":"AO Spiel","year":"2008","unstructured":"Spiel AO, Gilbert JC, Jilma B (2008) Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117(11):1449\u20131459. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.722827","journal-title":"Circulation"},{"issue":"7","key":"6648_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071746","volume":"12","author":"H Awada","year":"2020","unstructured":"Awada H, Voso MT, Guglielmelli P, Gurnari C (2020) Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers (Basel) 12(7):1746. https:\/\/doi.org\/10.3390\/cancers12071746","journal-title":"Cancers (Basel)"},{"key":"6648_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","volume":"41","author":"A Rottenstreich","year":"2017","unstructured":"Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y (2017) Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med 41:49\u201354. https:\/\/doi.org\/10.1016\/j.ejim.2016.11.011","journal-title":"Eur J Intern Med"},{"issue":"20","key":"6648_CR22","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"4","key":"6648_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"3","key":"6648_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/rth2.12315","volume":"4","author":"M Sacco","year":"2020","unstructured":"Sacco M, Ranalli P, Lancellotti S et al (2020) Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Res Pract Thromb Haemost 4(3):413\u2013421. https:\/\/doi.org\/10.1002\/rth2.12315","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"6648_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/life14040486","volume":"14","author":"R Castelli","year":"2024","unstructured":"Castelli R, Berzuini A, Manetti R et al (2024) ADAMTS13, von Willebrand factor, platelet microparticles, factor VIII, and impact of somatic mutations in the pathogenesis of splanchnic vein thrombosis associated with BCR-ABL-negative myeloproliferative neoplasms. Life 14(4):486. https:\/\/doi.org\/10.3390\/life14040486","journal-title":"Life"},{"issue":"1","key":"6648_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3324\/haematol.2018.195321","volume":"104","author":"A Guy","year":"2019","unstructured":"Guy A, Gourdou-Latyszenok V, Le Lay N et al (2019) Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica 104(1):70\u201381. https:\/\/doi.org\/10.3324\/haematol.2018.195321","journal-title":"Haematologica"},{"issue":"9","key":"6648_CR27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1055\/s-0038-1667015","volume":"118","author":"A Guadall","year":"2018","unstructured":"Guadall A, Lesteven E, Letort G et al (2018) Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features. Thromb Haemost 118(9):1586\u20131599. https:\/\/doi.org\/10.1055\/s-0038-1667015","journal-title":"Thromb Haemost"},{"issue":"12","key":"6648_CR28","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/jth.14304","volume":"16","author":"LL Swystun","year":"2018","unstructured":"Swystun LL, Lillicrap D (2018) Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost 16(12):2375\u20132390. https:\/\/doi.org\/10.1111\/jth.14304","journal-title":"J Thromb Haemost"},{"issue":"5","key":"6648_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCULATIONAHA.118.034532","volume":"139","author":"M Sabater-Lleal","year":"2019","unstructured":"Sabater-Lleal M, Huffman JE, de Vries PS et al (2019) Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and von Willebrand factor plasma levels. Circulation 139(5):620\u2013635","journal-title":"Circulation"},{"issue":"23","key":"6648_CR30","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1182\/bloodadvances.2024013777","volume":"8","author":"RK Venkat","year":"2024","unstructured":"Venkat RK, Redd RA, Harris AC (2024) Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Adv 8(23):6043\u20136054. https:\/\/doi.org\/10.1182\/bloodadvances.2024013777","journal-title":"Blood Adv"},{"issue":"4","key":"6648_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jtha.2023.12.024","volume":"22","author":"J Noye","year":"2024","unstructured":"Noye J, Beggs J, Mason J (2024) Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype. J Thromb Haemost 22(4):965\u2013974. https:\/\/doi.org\/10.1016\/j.jtha.2023.12.024","journal-title":"J Thromb Haemost"},{"issue":"5","key":"6648_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ajh.23676","volume":"89","author":"A Alvarez-Larr\u00e1n","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Bellosillo B, Pereira A et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89(5):517\u2013523. https:\/\/doi.org\/10.1002\/ajh.23676","journal-title":"Am J Hematol"},{"issue":"12","key":"6648_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C et al (2021) JAK2V617F variant allele frequency\u2009>\u200950% identifies patients with polycythemia Vera at high risk for venous thrombosis. Blood Cancer J 11(12):199 Published 2021 Dec 11. https:\/\/doi.org\/10.1038\/s41408-021-00581-6","journal-title":"Blood Cancer J"},{"key":"6648_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","volume":"211","author":"S Soudet","year":"2022","unstructured":"Soudet S, Le Roy G, Cadet E et al (2022) JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis. Thromb Res 211:1\u20135. https:\/\/doi.org\/10.1016\/j.thromres.2022.01.011","journal-title":"Thromb Res"},{"issue":"8","key":"6648_CR35","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","volume":"96","author":"I Bertozzi","year":"2017","unstructured":"Bertozzi I, Bogoni G, Biagetti G et al (2017) Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol 96(8):1297\u20131302. https:\/\/doi.org\/10.1007\/s00277-017-3040-8","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06648-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T20:02:40Z","timestamp":1763236960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06648-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6648"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06648-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}